EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 354 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR OncoArray Links Dozens of DNA Variants to Risk for Common Cancers June 12, 2018 New Low-Powered Implantable Device Monitors Soft Tissue for Signs of Breast... July 1, 2021 Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers May 2, 2018 Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... March 23, 2021 Load more HOT NEWS Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive... Our new strategy to make discoveries, drive progress, and bring hope Two Large Studies with New Screening Tests Show Promise for Increasing... Nanoparticle Trains Immune Cells to Attack Cancer
